ctDNA Assay in Patients With Resectable Pancreatic Cancer
The purpose of this study is to determine the proportion of positive ctDNA -freely circulating tumor DNA fragments found in the blood plasma- in patients with pancreatic cancer and to better understand the relationship between possible ctDNA biomarkers and patient survival. A successful study may provide preliminary evidence that helps improve future patient care through targeted diagnostics, prognosis, and/or treatment.
|Condition or Disease||Intervention/Treatment||Phase|
The objective of this study is to assess the role of serial ctDNA analysis as integrative biomarker in patients with resectable or borderline resectable pancreatic cancer undergoing treatment with curative intent. This is a single arm prospective tissue/blood collection from patients undergoing neoadjuvant treatment and Surgery as well as surveillance, plan to accrue up to 50 patients. Primary objective is to determine the proportion of ctDNA positive in patients with resectable pancreatic cancer and to evaluate the progression free survival (PFS) in subjects with ctDNA positive versus ctDNA negative.
Patients who consent to the study will participate in pre-study exams and tests to find out if they can take part in the study. This includes, but is not limited to, a doctor's visit with medical history and physical evaluation, blood work, pregnancy test for those capable of becoming pregnant, and and imaging tests.
The study itself will include the patient's regular treatment for pancreatic cancer which may include 4 to 6 months of chemotherapy, chemo-radiation, surgery to remove pancreatic cancer, adjuvant chemotherapy and follow up for 5 years. Blood will be drawn at regular time points during this study for ctDNA detection. The tumor tissue at diagnosis will be collected to develop a personalized and tumor informed PCR test.
Primary Outcome Measures
- ctDNA Positivity in Patients with Resectable Pancreatic Cancer [Baseline]
Determine the proportion of ct DNA positivity in patients with resectable pancreatic cancer.
- Progression free survival (PFS) [2 years]
Determine PFS in ctDNA positive versus ctDNA negative patients.
Secondary Outcome Measures
- Conversion time from ctDNA negative to positive after surgical resection. [2 years]
Median time from positive ctDNA to negative ctDNA in patients with pancreatic cancer undergoing surgical resection and adjuvant chemotherapy
- Median time for select genes to convert from positive to negative. [2 years]
Median time from any positive KRAS, CDKN2A, SMAD4, or TP53 genes to become negative
- Overall survival (OS) in ctDNA positive versus ctDNA negative. [2 years]
Comparison of overall survival rate of ctDNA positive versus ctDNA negative patients.
Newly diagnosed exocrine pancreatic cancer with pathology confirmed as adenocarcinoma
Resectable/Borderline Resectable Pancreatic cancer as defined by the NCCN guidelines
≥ 18 years old at the time of informed consent
ECOG Performance Status 0, or 1
Patients who are candidates for standard of care (SOC) neoadjuvant chemotherapy. Patients may be enrolled in a clinical trial.
Ability to provide written informed consent and HIPAA authorization
Patient must agree on blood collection at assigned time points for biomarker analysis
Patients must have a life expectancy of at least 6 months
Patients with pancreatic malignant tumor histologically confirmed as neuroendocrine or any other type of malignancies
Positive pregnancy test, pregnant, or breastfeeding
Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study
Contacts and Locations
LocationsNo locations specified.
Sponsors and Collaborators
- University of Oklahoma
- Natera, Inc.
Study Documents (Full-Text)None provided.